BioHedge Weekly
13D/13G filings from 18 institutional investors, cross-referenced with trial events and regulatory filings. Part of the RxDataLab platform with clinical trials, SEC filings, and hedge fund positioning, linked by company.
Weekly Delivery
Get next week's BioHedge Weekly by email
One email per week. We follow up on coverage that's relevant to you.
or email [email protected]
Weekly Filing Volume
Filings This Week
| Fund / Company | Ownership & Type |
|---|---|
OrbiMed RAPT THERAPEUTICS INC (RAPT) | 0.0% 13G/A [SEC] |
OrbiMed Forte Biosciences, Inc. (FBRX) | 4.3% -3.7 13G/A [SEC] |
OrbiMed NeuroPace (NPCE) | 6.2% -1.8 13G/A [SEC] |
OrbiMed Avalo Therapeutics, Inc. (AVTX) | 2.1% -4.3 13G/A [SEC] |
Perceptive Advisors Amylyx Pharmaceuticals, Inc. (AMLX) | 7.5% -0.7 13G/A [SEC] |
Perceptive Advisors INHIBIKASE THERAPEUTICS INC (IKT) | 8.9% -1.1 13G/A [SEC] |
Perceptive Advisors PALISADE BIO INC (PALI) | 7.9% 13G/A [SEC] |
Perceptive Advisors | 4.6% 13G/A [SEC] |
Perceptive Advisors X4 Pharmaceuticals, Inc (XFOR) | 7.3% -0.3 13G/A [SEC] |
Perceptive Advisors RHYTHM PHARMACEUTICALS, INC. (RYTM) | 5.1% -1.7 13G/A [SEC] |
Perceptive Advisors Traws Pharma, Inc. (TRAW) | 6.1% -3.9 13G/A [SEC] |
Perceptive Advisors Inhibrx Biosciences, Inc. (INBX) | 10.0% 13G/A [SEC] |
Perceptive Advisors CYTOMX THERAPEUTICS INC (CTMX) | 4.6% -1.3 13G/A [SEC] |
Perceptive Advisors Adagio Medical (ADGM) | 55.4% -2.1 13G/A [SEC] |
Perceptive Advisors Aldeyra Therapeutics, Inc. (ALDX) | 0.0% 13G/A [SEC] |
| 55 more filings. View them all on the RxDataLab platform | |
New Positions
Funds disclosing more than 5% ownership in a company for the first time.
| Fund / Company | Ownership & Type |
|---|---|
Cormorant Asset Management, LP Rallybio Corp (RLYB) | 7.6% SC 13G [SEC] |
MPM BioImpact Forte Biosciences, Inc. (FBRX) | 7.2% SC 13G [SEC] |
Baker Brothers Advisors Praxis Precision Medicines, Inc. (PRAX) | 6.3% SC 13G [SEC] |
Multi-Fund Activity
Companies with filings from multiple institutional investors this week.
| Company | Funds | Net Change |
|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | 3 | -4.3% |
| TENAX THERAPEUTICS, INC. (TENX) | 2 | -3.6% |
| Forte Biosciences, Inc. (FBRX) | 2 | +3.5% |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2 | +0.0% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2 | +3.7% |
| Foghorn Therapeutics Inc. (FHTX) | 2 | +18.6% |
| Werewolf Therapeutics, Inc. (HOWL) | 2 | -2.8% |
| PALISADE BIO INC (PALI) | 2 | +17.8% |
About This Data
Schedule 13D/13G filings are SEC disclosures that report beneficial ownership. They are required when an investor acquires more than 5% of a company's shares. Schedule 13D filings indicate activist intent (potential influence over company direction), while 13G filings indicate passive investment.
New positions are filings where a fund discloses more than 5% ownership in a company for the first time.
We track 18 biotech-focused institutional investors with known sector expertise.
Data from RxDataLab and the SEC.